QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
NASDAQ:KPRX

Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis

$0.68
+0.06 (+10.19%)
(As of 01:15 PM ET)
Today's Range
$0.60
$0.69
50-Day Range
$0.54
$0.85
52-Week Range
$0.46
$5.25
Volume
334,469 shs
Average Volume
1.66 million shs
Market Capitalization
$5.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Kiora Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
976.9% Upside
$7.00 Price Target
Short Interest
Healthy
1.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Kiora Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.32 out of 5 stars

KPRX stock logo

About Kiora Pharmaceuticals Stock (NASDAQ:KPRX)

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

KPRX Stock Price History

KPRX Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 3.8%
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Kiora Pharmaceuticals Inc KPRX
Kiora Pharmaceuticals reports Q3 results
Analyst Expectations for Kiora Pharmaceuticals's Future
See More Headlines
Receive KPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KPRX
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+1,034.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.99 per share

Miscellaneous

Free Float
7,617,000
Market Cap
$4.75 million
Optionable
Not Optionable
Beta
-0.28
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Brian M. Strem Ph.D. (Age 44)
    President, CEO & Director
    Comp: $464.93k
  • Ms. Melissa Tosca CPA (Age 44)
    Executive Vice President of Finance
    Comp: $282.28k
  • Dr. Eric J. Daniels M.B.A. (Age 50)
    M.D., Chief Development Officer
    Comp: $371.47k
  • Dr. Stefan Sperl Ph.D.
    Executive Vice President of CMC & Operations

KPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiora Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KPRX shares.
View KPRX analyst ratings
or view top-rated stocks.

What is Kiora Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 12 month price targets for Kiora Pharmaceuticals' shares. Their KPRX share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 976.9% from the stock's current price.
View analysts price targets for KPRX
or view top-rated stocks among Wall Street analysts.

How have KPRX shares performed in 2024?

Kiora Pharmaceuticals' stock was trading at $0.5224 at the beginning of 2024. Since then, KPRX shares have increased by 24.4% and is now trading at $0.65.
View the best growth stocks for 2024 here
.

Are investors shorting Kiora Pharmaceuticals?

Kiora Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 86,400 shares, an increase of 51.6% from the February 29th total of 57,000 shares. Based on an average daily volume of 1,560,000 shares, the short-interest ratio is presently 0.1 days. Currently, 1.2% of the company's stock are sold short.
View Kiora Pharmaceuticals' Short Interest
.

When is Kiora Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our KPRX earnings forecast
.

How were Kiora Pharmaceuticals' earnings last quarter?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) posted its quarterly earnings data on Monday, November, 15th. The company reported ($11.60) EPS for the quarter, topping analysts' consensus estimates of ($13.48) by $1.88.

When did Kiora Pharmaceuticals' stock split?

Kiora Pharmaceuticals shares reverse split on Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Kiora Pharmaceuticals' major shareholders?

Kiora Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (1.20%).

How do I buy shares of Kiora Pharmaceuticals?

Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KPRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners